JeffreyJ.PuMDPh.D.

PubMed

• 1 citations
  Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference.
  Andrew Wang, James Liu, Jeffrey J Pu> ;Journal of Hematology & Oncology. 2023 May 12
• 8 citations
  Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia.
  Gongqiang Wu, Shanshan Guo, Qian Luo, Xiaoxia Wang, Wenhai Deng, Guifang Ouyang, Jeffrey J Pu, Wen Lei, Wenbin Qian> ;Frontiers in Immunology. 2023 Jan 1
• The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation.
  Hao Wang, Kristin N Berger, Elizabeth L Miller, Wei Fu, Larisa Broglie, Frederick D Goldman, Heiko Konig, Su Jin Lim, Arthur S Berg, Julie-An Talano, Melanie A Comito,...> ;Therapeutic Advances in Hematology. 2023 Jan 1
• 20 citations
  Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
  Meghan C Thompson, Rosemary A Harrup, Catherine C Coombs, Lindsey E Roeker, Jeffrey J Pu, Michael Y Choi, Paul M Barr, John N Allan, Martin Šimkovič, Lori Leslie, Joan...> ;Blood Advances. 2022 Aug 9
• 1 citations
  The role of adjuvant chemotherapy in the management of acute promyelocytic leukemia differentiation syndrome.
  Dominic LaBella, Samuel Regan, Heiko Konig, Daniel N Egan, Neil A Bailey, Raya Mawad, Morgan Gilbert, John M Pagel, Jeffrey J Pu> ;Frontiers in Oncology. 2022 Jan 1
• 9 citations
  Mantle cell lymphoma management trends and novel agents: where are we going?
  Jeffrey J Pu, Malvi Savani, Nick Huang, Elliot M Epner> ;Therapeutic Advances in Hematology. 2022 Jan 1
• Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.
  Francis R LeBlanc, Zainul S Hasanali, August Stuart, Sara Shimko, Kamal Sharma, Violetta V Leshchenko, Samir Parekh, Haiqing Fu, Ya Zhang, Melvenia M Martin, Mark Kest...> ;Oncotarget. 2022 Jan 1
• 3 citations
  PIGN spatiotemporally regulates the spindle assembly checkpoint proteins in leukemia transformation and progression
  Emmanuel K. Teye, Shasha Lu, Fangyuan Chen, Wenrui Yang, Thomas Abraham, Douglas B Stairs, Hong Gang Wang, Gregory S Yochum, Robert A. Brodsky, Jeffrey J. Pu> ;Scientific Reports. 2021 Sep 24
• 16 citations
  CD70-targeting CAR-T cells have potential activity against CD19-negative B-cell Lymphoma.
  Wenhai Deng, Panpan Chen, Wen Lei, Yang Xu, Nengwen Xu, Jeffrey J. Pu, Aibin Liang, Wenbin Qian> ;Cancer Communications. 2021 Jul 27
• 46 citations
  COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
  Lindsey E. Roeker, Toby A. Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander Coltoff, Matthew S. Davids, PK Baker, Lori A. Leslie, Kerry A. Rogers, John N. Allan, Ra...> ;Blood. 2021 Jul 23
• 35 citations
  Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.
  Jing Zhou Hou, Jing Christine Ye, Jeffrey J. Pu, Hongtao Liu, Wei Ding, Hong Zheng, Delong Liu> ;Journal of Hematology & Oncology. 2021 Apr 21
• Resolution of Chronic Immune Thrombocytopenia Purpura after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B-Cell Lymphoma
  Prashanth Ashok Kumar, Ali Wazir, Jeffrey J. Pu> ;Journal of Medical Cases. 2021 Jan 1
• 29 citations
  Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
  Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster, Nicole Lamanna, John M. Pagel, Ian W. Flinn, Jacqueline C. Barrientos, Kanti R. Rai, James A. Reeves, Bruce D. Ch...> ;Blood. 2021 May 20
• 43 citations
  Alternative Polyadenylation: a new frontier in post transcriptional regulation.
  Fanggang Ren, Na Zhang, Lan Zhang, Jeffrey J. Pu, Eric W. Miller> ;Biomarker Research. 2020 Nov 25
• 12 citations
  Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world set...
  Antonio Cuneo, Anthony R. Mato, Gian Matteo Rigolin, Alfonso Piciocchi, Massimo Gentile, Luca Laurenti, John N. Allan, John M. Pagel, Danielle M. Brander, Brian T. Hil...> ;Cancer Medicine. 2020 Sep 24
• 220 citations
  Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Blood. 2020 Sep 3
• 9 citations
  The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy.
  Chaitra S. Ujjani, Anthony R. Mato, Brian T. Hill, John N. Allan, Frederick Lansigan, Ryan Jacobs, Alan P Skarbnik, Hande H. Tuncer, John M. Pagel, Danielle M. Brander...> ;Blood and Lymphatic Cancer. 2020 Aug 24
• 2 citations
  The relationship between regulatory T cells and radiation therapy.
  P.-F. Hou, L.-J. Zhu, Y. Pan, X.-C. Sun, J. Pu> ;Cancer Radiotherapie. 2020 Feb 8
• 74 citations
  Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.
  Anthony R. Mato, Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna, Danielle M. Brander, Mazyar Shadman, Chaitra S. Ujjani, Maryam Sarraf Yazdy, Guilherme ...> ;Clinical Cancer Research. 2020 Jul 15
• 16 citations
  Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma.
  Stephen E. Spurgeon, Kamal Sharma, David F. Claxton, Christopher Ehmann, Jeffrey J. Pu, Sara Shimko, August Stewart, N. Subbiah, Gundula Palmbach, Francis LeBlanc, Emi...> ;British Journal of Haematology. 2019 Sep 1
• 7 citations
  Impact of ruxolitinib on myelofibrosis patients post allogeneic stem cell transplant-a pilot study.
  Jeffrey J. Pu, Joyson Poulose, Junjia Zhu, Julie Fanburg-Smith, David F. Claxton, Michael G. Bayerl> ;British Journal of Haematology. 2019 Sep 1
• 3 citations
  Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient.
  Samuel Regan, Xuebin Yang, Niklas Finnberg, Wafik S. El-Deiry, Jeffrey J. Pu> ;Cancer Biology & Therapy. 2019 Aug 18
• 25 citations
  Mantle cell lymphoma and its management: where are we now?
  Abdullah Ladha, Jianzhi Zhao, Elliot M. Epner, Jeffrey J. Pu> ;Experimental Hematology & Oncology. 2019 Jan 30
• 50 citations
  Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
  Anthony R. Mato, Lindsey E. Roeker, John N. Allan, John M. Pagel, Danielle M. Brander, Brian T. Hill, Bruce D. Cheson, Richard R. Furman, Nicole Lamanna, Constantine S...> ;American Journal of Hematology. 2018 Nov 1
• 292 citations
  Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
  Anthony R. Mato, Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander, Brian T. Hill, Christina Howlett, Alan P Skarbnik, Bruce D. Cheson, Clive S. Z...> ;Haematologica. 2018 May 1
• Join now to see all

Abstracts/Posters

• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Jeffrey J Pu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019